High Risk Breast Lesions Identified on MRI-guided Vacuum-assisted needle biopsy: Outcome of Surgical Excision and Imaging Follow-up
Overview
Authors
Affiliations
Objective:: To determine whether breast MRI-guided vacuum-assisted biopsy (MRI-VAB) high-risk lesion histology influences surgical or long-term imaging follow-up outcomes.
Methods:: Patients with imaging-concordant high-risk findings on 9-gauge breast MRI-VAB between January 2007 and July 2012 who had surgical histopathology or 2 year imaging follow-up were retrospectively reviewed.
Results:: 90 patients with 99 lesions were included. Lesions were atypical ductal hyperplasia (ADH) (n = 21), lobular neoplasia [n = 36; atypical lobular hyperplasia (ALH) (n = 22), lobular carcinoma in situ (LCIS) (n = 6), and ALH plus LCIS (n = 8)], and other high-risk lesion (n = 42; papillary lesions, radial scar, flat epithelial atypia, atypia unspecified). Of 53 excised lesions, 6 (11%) were upgraded to invasive cancer or ductal carcinoma in situ (DCIS). 4 of 21 (19%) ADH lesions were upgraded to DCIS. 2 of 36 (6%) lobular neoplasia lesions, both combined ALH and LCIS, were upgraded to DCIS, and invasive lobular carcinoma, respectively. The remaining 46 lesions were managed conservatively with imaging follow-up: 17 (37%) had mammography only, while 29 (63%) had mammography and MRI follow-up. There was no evidence of breast cancer development at the site of MRI-VAB in the cases with only imaging follow-up.
Conclusion:: We conclude that the upgrade rate for high-risk lesions at MRI-VAB at surgical excision is low. Surgical excision is warranted for ADH and combined ALH-LCIS lesions. For other lesions, a multidisciplinary approach to decide on personalized management may be appropriate.
Advances In Knowledge:: Surgical excision is warranted for ADH lesions and combined ALH-LCIS lesions identified at breast MRI-VAB. A multidisciplinary approach to patient management of other high-risk lesions may be appropriate.
Rescinito G, Brunetti N, Garlaschi A, Tosto S, Gristina L, Conti B Radiol Med. 2024; 129(5):767-775.
PMID: 38512628 PMC: 11088538. DOI: 10.1007/s11547-024-01808-9.
Chung H, Middleton L, Sun J, Whitman G Breast Cancer Res Treat. 2024; 205(3):545-554.
PMID: 38472593 DOI: 10.1007/s10549-024-07261-6.
Laws A, Leonard S, Hershey E, Stokes S, Vincuilla J, Sharma E Ann Surg Oncol. 2024; 31(5):3120-3127.
PMID: 38261128 DOI: 10.1245/s10434-024-14947-0.
Ozcan B, Yan J, Xi Y, Baydoun S, Scoggins M, Dogan B Eur J Breast Health. 2023; 19(1):1-27.
PMID: 36605469 PMC: 9806944. DOI: 10.4274/ejbh.galenos.2022.2022-12-1.
Cha E, Ambinder E, Oluyemi E, Mullen L, Panigrahi B, Rossi J Breast Cancer Res Treat. 2022; 196(3):517-525.
PMID: 36242709 DOI: 10.1007/s10549-022-06761-7.